Business
PetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December
PetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n PetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December\n \n \nPetLife to Start New Pre-Clinical Study on Escozine for Pets; Results Expected in December\n \n BEVERLY HILLS, CA--(Marketwired - Oct 27, 2014) - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a registered US Veterinary Pharmaceutical company, today announced it has signed an agreement with AllCells to start a pre-clinical study on its major product Escozine for Pets™ with the most common canine cancer tumor cell lines (lymphoma and osteosarcoma). Results are expected in December, after which the Company will announce the conclusions as well as post the Study's final report on its website.\n Escozine for Pets™ contains a patented, high-potency bioactive anti-cancer compound, which the Company believes enables the expanding Escozine for Pets product line to become one of the leading medications and nutraceutical products for the treatment and prevention of cancer in companion animals as well as livestock.\n PetLife has engaged Alameda, California-based AllCells, founded in 1998, for its reputation as a leading, global provider of advanced cellular research to academic and industrial research laboratories, government institutions, and pharmaceutical companies throughout North America, Europe, Asia and Japan. \n As stated in the AllCells' Statement of Work, the canine tumor cell lines will be treated with Escozine for Pets™ and, using flow cytometry, samples will be analyzed for apoptosis (cell death) and necrosis at 48 and 72-hour intervals. The cell count and percent of apoptosis and necrosis will be calculated to determine the product's efficacy. The University of California, Davis, will be providing the osteosarcoma cell line for this study.\n PetLife's sister company, Medolife Corp., previously has conducted pre-clinical studies with its similar product, 'Escozine for humans' on human cancer cell lines at the University of California, San Diego's Moores Cancer Center and received positive results. Those results showed up to 95 percent apoptosis of cancer cells when using Escozine, as well as positive synergistic effects when combined with a variety of traditional chemotherapy treatments. \n Animal cancer cells respond to anti-cancer drugs the same as do human cancer cells. PetLife anticipates that the...